All In Biotech

Drug Trial Radar · NCT05458297

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 189 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

189

Planned (sponsor's estimate)

Start

Jul 21, 2022

Primary completion

May 17, 2029

Study completion May 17, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. * Cohort A: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 2 prior systemic therapies including a Bruton's tyrosine kinase inhibition/inhibitor (BTKi), and post therapy chimeric antigen receptor T (CAR-T) cell therapy or ineligible for CAR-T cell therapy * Cohort B: Participants with relapsed or refractory RT disease after at least 1 prior systemic therapy * Cohort C: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 1 prior systemic therapy and no prior exposure to a non-covalent BTKi * Cohort D: Participants with relapsed or refractory FL and CLL relapsed or refractory disease after at least 2 prior systemic therapies and have no other available therapy * Cohort E: Participants with relapsed or refractory FL after at least 2 prior systemic therapies and have no other available therapy The primary study hypothesis is that zilovertamab vedotin monotherapy has an increased Objective Response Rate (ORR) per Lugano Response Criteria as assessed by blinded independent central review (BICR). As of Amendment 07, Cohort D is closed to enrollment of participants with CLL and enrollment of participants into Arm 2 (zilovertamab vedotin at Dose 2 on Days 1 \& 8 of each 3 Week Cycle (Q2/3W)). As of Amendment 09, no additional participants with RT will be enrolled in Cohort B; however, those currently enrolled will continue with study intervention treatment (if applicable) until a protocol specified discontinuation criterion is met. Cohort E will be closed, as no participants with FL have been treated in this cohort.

Conditions

  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Richter Transformation Lymphoma

Interventions

  • Zilovertamab vedotinBiological

    IV infusion

  • NemtabrutinibDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with MCL (Cohort C), FL (Cohort D), and CLL (Cohort D) with ≥1 Adverse Event (AE)Time frame: Up to approximately 81 months
  2. Percentage of Participants with MCL (Cohort C), FL (Cohort D), and CLL (Cohort D) who Discontinue from Study Therapy Due to AETime frame: Up to approximately 81 months
  3. Percentage of Participants with MCL (Cohort C) who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 81 months
  4. Objective Response Rate (ORR) per Lugano Response Criteria as Assessed by Blinded Independent Central Review (BICR) in Participants with MCL (Cohort A), RT (Cohort B), and FL (Cohort D)Time frame: Up to approximately 81 months
  5. ORR per Lugano Response Criteria as Assessed by Investigator in Participants with MCL (Cohort C)Time frame: Up to approximately 81 months
  6. ORR per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by Investigator in Participants with CLL (Cohort D)Time frame: Up to approximately 81 months

Locations

109 sites in 21 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology ( Site 0037)

    Anchorage, Alaska

  • Banner MD Anderson Cancer Center ( Site 0040)

    Gilbert, Arizona

  • Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036)

    Phoenix, Arizona

  • University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008)

    Aurora, Colorado

  • Cancer Care Specialists of Illinois ( Site 0031)

    Decatur, Illinois

  • University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics ( Site 0038)

    Fairway, Kansas

  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007)

    Saint Matthews, Kentucky

  • Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010)

    Baltimore, Maryland

  • Tufts Medical Center ( Site 0024)

    Boston, Massachusetts

  • Massachusetts General Hospital ( Site 0018)

    Boston, Massachusetts

  • Dana-Farber Cancer Institute-Lymphoma ( Site 0026)

    Boston, Massachusetts

  • University of Michigan ( Site 0009)

    Ann Arbor, Michigan

  • Henry Ford Hospital ( Site 0035)

    Detroit, Michigan

  • Icahn School of Medicine at Mount Sinai ( Site 0023)

    New York, New York

  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014)

    Fargo, North Dakota

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0004)

    Columbus, Ohio

  • Avera Cancer Institute- Research ( Site 0011)

    Sioux Falls, South Dakota

  • Medical Oncology Associates, PS ( Site 0005)

    Spokane, Washington

  • University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030)

    Madison, Wisconsin

  • Medical College of Wisconsin ( Site 0021)

    Milwaukee, Wisconsin

  • Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1809)

    Rio de Janeiro, Brazil

  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808)

    São Paulo, Brazil

  • Hospital Paulistano-Americas Oncologia ( Site 1805)

    São Paulo, Brazil

  • Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807)

    Natal, Rio Grande do Norte, Brazil

  • BC Cancer Vancouver-Clinical Trials Unit ( Site 0201)

    Vancouver, British Columbia, Canada

  • The Moncton Hospital-Oncology ( Site 0211)

    Moncton, New Brunswick, Canada

  • QEII Health Sciences Centre - Victoria General Site ( Site 0213)

    Halifax, Nova Scotia, Canada

  • London Health Sciences Centre ( Site 0203)

    London, Ontario, Canada

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200)

    Toronto, Ontario, Canada

  • Jewish General Hospital ( Site 0202)

    Montreal, Quebec, Canada

  • Allan Blair Cancer Centre-Care Services ( Site 0208)

    Regina, Saskatchewan, Canada

  • IC La Serena Research ( Site 1909)

    La Serena, Coquimbo Region, Chile

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907)

    Santiago, Region M. de Santiago, Chile

  • Clínica Inmunocel ( Site 1910)

    Santiago, Region M. de Santiago, Chile

  • Clínica Alemana de Santiago ( Site 1903)

    Santiago, Region M. de Santiago, Chile

  • Beijing Cancer hospital ( Site 1200)

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center ( Site 1201)

    Guangzhou, Guangdong, China

  • Zhujiang Hospital ( Site 1207)

    Guangzhou, Guangdong, China

  • Southern Medical University Nanfang Hospital ( Site 1202)

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital-hematology department ( Site 1212)

    Zhengzhou, Henan, China

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.